Unicycive Therapeutics (UNCY) Registration filing summary

Company overview and business model

• Clinical-stage biotechnology company focused on therapies for significant unmet medical needs, initially targeting kidney disease.

• Business model centers on licensing technologies and drugs for development, regulatory approval, and commercialization in global markets.

• Two lead programs: oxylanthanum carbonate (OLC) for hyperphosphatemia in CKD patients on dialysis, and UNI-494 for acute kidney injury (AKI).

• Strategy includes U.S. drug approval followed by global partnerships.

• Management leverages industry expertise and networks to identify and acquire promising assets.

Financial performance and metrics

• As of June 5, 2026, 27,393,027 shares of common stock were issued and outstanding.

• Recent sale of 1,693,000 shares at an average price of $7.34 per share, raising approximately $11.2 million in net proceeds.

• Net tangible book value as of March 31, 2026 was $1.49 per share; pro forma as adjusted after the offering would be $2.74 per share.

• Offering could result in immediate dilution of $4.69 per share to new investors at the assumed offering price.

Use of proceeds and capital allocation

• Net proceeds intended for general corporate purposes, including product development, commercialization, R&D, administrative expenses, license or technology acquisitions, and working capital.

• Management retains broad discretion over allocation; may also use proceeds for debt repayment or acquisitions, though no current commitments exist.

• Pending use, proceeds will be invested in short-term, investment-grade, interest-bearing instruments.